Defending evidence isn't just important – it’s a necessity. Population Council president Julia Bunting illuminates the need for quality evidence and the uphill battle it currently faces in an op-ed featured at the Lancet Global Health blog.
In 1953, the Population Council awarded fellowships to its first class of promising young graduate students for advanced training in demography. Today, thousands of former Council staff and researchers are making an impact in global health and development around the world.
How can we protect vulnerable communities from HIV? How does quality of care impact health outcomes?
Many of the ideas and perspectives that seem self-evident today in fact first emerged from an observation, question or insight that challenged accepted norms years ago.
Since our founding, asking bold questions and delivering rigorous evidence to improve health and well-being has been at the heart of the Population Council. Our research has addressed critical health and development issues, from slowing the spread of HIV and AIDS to putting women and girls at the center of global development.
This November, we are proud to turn 65 and to reflect on some of our exciting contributions. We’re celebrating 65 years of Ideas, Evidence, and Impact and the collective efforts that have made this world a better place.
Join us as we unveil 10 ideas that changed the world in the lead-up to our 65th anniversary on November 7, 2017.
CAPE TOWN, SOUTH AFRICA — More than 60 new analyses from the Population Council will elevate the scientific discourse on critical health and development issues this week at the 2017 International Population Conference (IPC) in South Africa, with a particular focus on the risks and realities faced by adolescents.
The Population Council congratulates Vivian Brache on receiving Society of Family Planning’s 2017 Allan Rosenfield Award for Lifetime Contributions to International Family Planning.
First in-human clinical trial of griffithsin, a naturally occurring anti-HIV protein, which limits risk of cross-resistance to antiretroviral (ARV) products
NEW YORK, NY—The Population Council today announced the enrollment of the first participant in the Phase I clinical trial evaluating PC-6500 (griffithsin in a carrageenan gel), an investigational multipurpose technology to prevent HIV and sexually transmitted infections (STIs), two major threats to sexual health around the world. This is the first in-human study of griffithsin (GRFT), a naturally occurring algae protein that inhibits HIV and other pathogens, including Herpes Simplex Virus (HSV-2).
Today, there is widespread recognition that gender-based violence (GBV) is a human rights violation and pervasive global health challenge with many consequences for women and girls including physical injury, psychological trauma, unwanted pregnancy, and sexually transmitted infections, including HIV.